
News|Articles|September 1, 2003
Fondaparinux effective and well-tolerated for prevention of VTE in acutely ill patients
Fondaparinux (Arixtra, Organon/Sanofi-Synthelabo) given once daily significantly reduces the risk of venous thromboembolism (VTE) in acutely ill, hospitalized patients, according to data from the Arixtra for ThromboEmbolism prevention in a Medical Indications Study (ARTEMIS).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Advancing Equity and Access in Breast Cancer Care
2
Type 1 Diabetes Drug Tzield Under Expedited Review Through New FDA Program
3
Aflibercept 8 mg Shows Promise in Reducing Injection Burden | AAO 2025
4
Final Takeaways of the GALAXI-2 and GALAXI-3 Trials From Lead Investigators
5